A Fast and Easy to Use Diagnostic Technology for Detecting Disease Markers for Cancer and Infection
Section: For Industry
Categories: "Diagnostics" "Viruses, Chronic & Infectious Diseases"
Reference #: 2004-001
OTC Contact: Blaine Hackman, Ph.D. (Directory Information | Send a Message)
Description
Georgetown University is seeking a partner for the development and commercialization of an exciting new disease diagnostic system that tests for multiple antigen specific antibodies for diseases including cancer, Hepatitis C and HIV. In these assays, light is used to detect the presence of disease specific antibodies, allowing for easy and low cost analysis. Furthermore, this analysis can be done on human patient sera without the need for extensive purification, saving time, labor and reducing costs to the user when compared with existing techniques. Early detection of disease maximizes the potential for successful treatment and patient survival, so accurate and user friendly diagnostic technologies are in critical demand.
Applications
The methods developed allow for the detection of infectious diseases, chronic inflammatory disease, allergic reactions, autoimmune diseases and cancer. The invention allows for quantitative detection of various analytes, including antibodies, proteins, antigens, carbohydrates, and lipids, in any body fluid where the analyte may be found.Advantages
- Methods are simple, highly sensitivity and allow for rapid detection of an analyte from body fluids without lengthy purification techniques.
- Quantitative detection for monitoring the progress of the disease or condition and the response to treatment.
- Overcomes common problems associated with bacterial or yeast incorporating immunoassays
Stage of Development
The present invention utilizes reporter-antigen fusion proteins for immunoprecipitation assays that can quantitatively measure serum antibody reactivity with protein antigens. The luminescent reporter, Renilla Luciferase, has been successfully used in reporter-antigen fusion proteins in the detection of cancer, Hepatitis C and HIV. In these assays, the amount of light produced is proportional to the amount of soluble fusion protein captured by the antibody-bound beads, allowing for quantitative analysis.Relevant Publications
Burbelo et al. Rapid antibody quantification and generation of whole proteome antibody response profiles using LIPS (luciferase immunoprecipitation systems). Biochem Biophys Res Commun. 2007. 352(4):889-95.
INVENTORS: Peter D. Burbelo and Thomas L. Mattson
Patent Status
U.S. Patent Publication No. 2007/0259336 is currently pending
